Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases
Shots:
- Sanofi has licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases under their Dec 2019 deal
- As per the deal, Nurix used its DEL-AI platform to develop E3 ligase-targeting degraders, with Sanofi having rights to license them. Nurix can co-develop & co-promote up to 2 US products, sharing US profits & losses 50/50 & earning ex-US royalties, while non-optioned programs yield milestones & global royalties
- Nurix received a total of $105M till date under this alliance, incl. $55M upfront, $15M license extension fee, & $22M for expansion, plus is eligible to get ~$465M in development, regulatory, & commercial milestones/licensed program as well as royalties on future sales
Ref: Nurix Therapeutics | Image: Sanofi & Nurix Therapeutics
Related News:- Alnylam Pharmaceuticals and Sanofi Report the US FDA’s Approval of Qfitlia (Fitusiran) to Treat Hemophilia A or B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
